Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer: primary endpoint results, effect estimate…
- CompassHER2Independent statistical analysis of CompassHER2 (NCT04266249), a phase 2 non-randomized trial evaluating recurrence-free survival after pre-surgery chemotherapy and targeted therapy in breast cancer.
- Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC): Complete Statistical AnalysisIndependent statistical analysis of Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02662608).
- COMPETEIndependent statistical analysis of Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03049189).
- Concentration and Activity of Lapatinib in Vestibular Schwannomas: Complete Statistical AnalysisIndependent statistical analysis of Concentration and Activity of Lapatinib in Vestibular Schwannomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00863122).
- Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED): primary endpoint results,…
- CONFIRMIndependent statistical analysis of Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.: primary endpoint…
- Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Conservative Treatment of Postprostatectomy Incontinence: Complete Statistical AnalysisIndependent statistical analysis of Conservative Treatment of Postprostatectomy Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00212264).
- Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior: Complete Statistical AnalysisIndependent statistical analysis of Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer:…
- Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Contrast-enhanced Ultrasound Evaluation of Chemoembolization: Complete Statistical AnalysisIndependent statistical analysis of Contrast-enhanced Ultrasound Evaluation of Chemoembolization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02764801).
- Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- COPEIndependent statistical analysis of A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- CoQ10Independent statistical analysis of Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CORALA statistical analysis of the CORAL phase 3 trial comparing R-ICE versus R-DHAP in patients aged 18–65 with relapsed diffuse large B-cell lymphoma. Includes trial design, endpoints, planned statistical methods, and interpretation…
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01653158).
- CPIT001Independent statistical analysis of Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old: Complete Statistical AnalysisIndependent statistical analysis of CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients: Complete Statistical AnalysisIndependent statistical analysis of CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients: primary endpoint results, effect estimate with confidence interval,…
- CRC027Independent statistical analysis of Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Creative Arts Therapy (CAT) in the Center for Cancer and Blood Disorders: Complete Statistical AnalysisIndependent statistical analysis of Creative Arts Therapy (CAT) in the Center for Cancer and Blood Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- CRISTALLOIndependent statistical analysis of A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT…
- Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy: Complete Statistical AnalysisIndependent statistical analysis of Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01388777).
- Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis: Complete Statistical AnalysisIndependent statistical analysis of Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CSISP-MENC1Independent statistical analysis of Immunogenicity of the Booster Dose of Two MenC Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00392808).
- Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer: Complete Statistical AnalysisIndependent statistical analysis of CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry: Complete Statistical AnalysisIndependent statistical analysis of CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CYTOFLOCIndependent statistical analysis of Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03529669).
- Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites: Complete Statistical AnalysisIndependent statistical analysis of Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites: primary endpoint results, effect estimate with confidence interval,…
- Dacarbazine and Carmustine in Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Dacarbazine and Carmustine in Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01692691).
- Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance: Complete Statistical AnalysisIndependent statistical analysis of Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung: Complete Statistical AnalysisIndependent statistical analysis of Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02048722).
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: Complete Statistical AnalysisIndependent statistical analysis of Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: Complete Statistical AnalysisIndependent statistical analysis of Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…